Latest from University of Illinois Cancer Center

Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.
Given the "addiction" of many tumors to mutant RAS for their survival, there has been renewed interest in developing new ways to inhibit RAS in cancer.
Publication Bottom Border
Border Publication